Arizona Couple Details 'Life-Changing’ Experience on Weight Loss Drugs — Including ‘Sulphur Burps’
Michael Carroll didn't go out in public and couldn't put on his own socks. Then he and wife Julie began taking a GLP-1 ...
FDA approves first-ever medication for obstructive sleep apnea
“Today’s approval marks the first drug treatment option for certain patients with obstructive sleep apnea,” said Sally Seymour, M.D., director of the Division of Pulmonology, Allergy, and Critical ...
Zepbound will dominate obesity market following SURMOUNT-5 results, says analyst
According to key opinion leaders, positive SURMOUNT-5 results, alongside Lilly’s business strategy, means Zepbound is set to ...
verywellhealth3h
Zepbound Gets FDA Approval to Treat Sleep Apnea
The obesity medication Zepbound can be used on-label to treat obstructive sleep apnea in adults with obesity, the FDA ...
Zacks.com on MSN4hOpinion
5 Large Drug Stocks to Keep An Eye On in the New Year
The drug and biotech industry had a tough time in the past couple of months after Trump announced the appointment of Robert F ...
US Employer Health Costs To Rise In 2025 Fueled By Weight Loss: Report
Eli Lilly's Zepbound is challenging Wegovy in the obesity market, while U.S. health care costs are set to rise 9% in 2025, driven by specialty drugs and inflation.
Cases of 'rabbit fever' increase over last decade
Cases of a bacterial infection called "rabbit fever" have been increasing during the past decade, according to the U.S.
Tirzepatide outpacing Wegovy in the obesity space
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/95.C_N2kNfW.js ...
FiercePharma7h
Lilly’s Zepbound expected to surpass Novo’s Wegovy to ‘dominate’ obesity market: GlobalData
Since Zepbound was approved by the FDA to treat obesity in late 2023, its maker Eli Lilly has been steadily closing in on ...